Beau M. Ances

Beau M. Ances

Auto-generated profile, based on publicly available information

Beau M. Ances

Department of Neurology, Washington University School of Medicine, St. Louis, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2016 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
MBMatthew R. Brier
Matthew R. Brier
BGBrian Gordon
Brian Gordon
KFKarl Friedrichsen
Karl Friedrichsen
JMJohn McCarthy
John McCarthy
ASAri Stern
Ari Stern
BABeau M. Ances
Beau M. Ances
PET imaging of pathological tau correlates more closely with Alzheimer’s disease–related cognitive impairment than does imaging of β-amyloid.

1 November 2013 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
DCDavid B Clifford
David B Clifford
BABeau M Ances
Beau M Ances

27 June 2012 in The Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
MBMathew R. Brier
Mathew R. Brier
JTJewell B. Thomas
Jewell B. Thomas
ASAbraham Z. Snyder
Abraham Z. Snyder
TBTammie Benzinger
Tammie Benzinger
DZDongyang Zhang
Dongyang Zhang
BABeau M. Ances
Beau M. Ances
Alzheimer9s disease (AD) is the most common cause of dementia. Much is known concerning AD pathophysiology but our understanding of the disease at the systems level remains incomplete. Previous AD research has used resting-state functional connectivity magnetic resonance imaging (rs-fcMRI) to assess the integrity of functional networks within the brain. Most studies have focused on the default-mode network (DMN), a primary locus of AD pathology. However, other brain regions are inevitably affected with disease progression. We studied rs-fcMRI in five functionally defined brain networks within a large cohort of human participants of either gender (n = 510) that ranged in AD severity from unaffected [clinical dementia rating (CDR) 0] to very mild (CDR 0.5) to mild (CDR 1). We observed loss of correlations within not only the DMN but other networks at CDR 0.5. Within the salience network (SAL), increases were seen between CDR 0 and CDR 0.5. However, at CDR 1, all networks, including SAL, exhibited reduced correlations. Specific networks were preferentially affected at certain CDR stages. In addition, cross-network relations were consistently lost with increasing AD severity. Our results demonstrate that AD is associated with widespread loss of both intranetwork and internetwork correlations. These results provide insight into AD pathophysiology and reinforce an integrative view of the brain9s functional organization.

21 September 2005 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RVRoberta Vitaliani
Roberta Vitaliani
WMWarren Mason
Warren Mason
BABeau Ances
Beau Ances
TZTheodore Zwerdling
Theodore Zwerdling
ZJZhilong Jiang
Zhilong Jiang
JDJosep Dalmau
Josep Dalmau

28 November 2012 in Brain
Verified
Journal Article
Closed access
CHCarl D. Hacker
Carl D. Hacker
JPJoel S. Perlmutter
Joel S. Perlmutter
SCSusan R. Criswell
Susan R. Criswell
BABeau M. Ances
Beau M. Ances
ASAbraham Z. Snyder
Abraham Z. Snyder
Classical accounts of the pathophysiology of Parkinson's disease have emphasized degeneration of dopaminergic nigrostriatal neurons with consequent dysfunction of cortico-striatal-thalamic loops. In contrast, post-mortem studies indicate that pathological changes in Parkinson's disease (Lewy neurites and Lewy bodies) first appear primarily in the lower brainstem with subsequent progression to more rostral parts of the neuraxis. The nigrostriatal and histological perspectives are not incompatible, but they do emphasize different anatomical structures. To address the question of which brain structures are functionally most affected by Parkinson's disease, we performed a resting-state functional magnetic resonance imaging study focused on striatal functional connectivity. We contrasted 13 patients with advanced Parkinson's disease versus 19 age-matched control subjects, using methodology incorporating scrupulous attention to minimizing the effects of head motion during scanning. The principal finding in the Parkinson's disease group was markedly lower striatal correlations with thalamus, midbrain, pons and cerebellum. This result reinforces the importance of the brainstem in the pathophysiology of Parkinson's disease. Focally altered functional connectivity also was observed in sensori-motor and visual areas of the cerebral cortex, as well the supramarginal gyrus. Striatal functional connectivity with the brainstem was graded (posterior putamen > anterior putamen > caudate), in both patients with Parkinson's disease and control subjects, in a manner that corresponds to well-documented gradient of striatal dopaminergic function loss in Parkinson's disease. We hypothesize that this gradient provides a clue to the pathogenesis of Parkinson's disease.

11 May 2005 in Brain
Verified
Journal Article
Open access
PDF file
BABeau M. Ances
Beau M. Ances
RVRoberta Vitaliani
Roberta Vitaliani
RTRobert A. Taylor
Robert A. Taylor
DLDavid S. Liebeskind
David S. Liebeskind
AVAlfredo Voloschin
Alfredo Voloschin
JDJosep Dalmau
Josep Dalmau
We report seven patients, six from a single institution, who developed subacute limbic encephalitis initially considered of uncertain aetiology. Four patients presented with symptoms of hippocampal dysfunction (i.e. severe short-term memory loss) and three with extensive limbic dysfunction (i.e. confusion, seizures and suspected psychosis). Brain MRI and [18F]fluorodeoxyglucose (FDG)-PET complemented each other but did not overlap in 50% of the patients. Combining both tests, all patients had temporal lobe abnormalities, five with additional areas involved. In one patient, FDG hyperactivity in the brainstem that was normal on MRI correlated with central hypoventilation; in another case, hyperactivity in the cerebellum anticipated ataxia. All patients had abnormal CSF: six pleocytosis, six had increased protein concentration, and three of five examined had oligoclonal bands. A tumour was identified and removed in four patients (mediastinal teratoma, thymoma, thymic carcinoma and thyroid cancer) and not treated in one (ovarian teratoma). An immunohistochemical technique that facilitates the detection of antibodies to cell surface or synaptic proteins demonstrated that six patients had antibodies to the neuropil of hippocampus or cerebellum, and one to intraneuronal antigens. Only one of the neuropil antibodies corresponded to voltage-gated potassium channel (VGKC) antibodies; the other five (two with identical specificity) reacted with antigens concentrated in areas of high dendritic density or synaptic-enriched regions of the hippocampus or cerebellum. Preliminary characterization of these antigens indicates that they are diverse and expressed on the neuronal cell membrane and dendrites; they do not co-localize with VGKCs, but partially co-localize with spinophilin. A target autoantigen in one of the patients co-localizes with a cell surface protein involved in hippocampal dendritic development. All patients except the one with antibodies to intracellular antigens had dramatic clinical and neuroimaging responses to immunotherapy or tumour resection; two patients had neurological relapse and improved with immunotherapy. Overall, the phenotype associated with the novel neuropil antibodies includes dominant behavioural and psychiatric symptoms and seizures that often interfere with the evaluation of cognition and memory, and brain MRI or FDG-PET abnormalities less frequently restricted to the medial temporal lobes than in patients with classical paraneoplastic or VGKC antibodies. When compared with patients with VGKC antibodies, patients with these novel antibodies are more likely to have CSF inflammatory abnormalities and systemic tumours (teratoma and thymoma), and they do not develop SIADH-like hyponatraemia. Although most autoantigens await characterization, all share intense expression by the neuropil of hippocampus, with patterns of immunolabelling characteristic enough to suggest the diagnosis of these disorders and predict response to treatment.